Prospective randomized controlled study on bestatin in resectable gastric cancer

Biomed Pharmacother. 1991;45(2-3):121-4. doi: 10.1016/0753-3322(91)90132-d.


The efficacy of Bestatin as adjuvant immunochemotherapy in patients with resectable gastric cancer was investigated. Ninety-six patients with similar background factors were randomized into 2 groups: a control group and an experimental group, the patients in the latter group receiving a daily oral dose of 60 mg Bestatin over a long period. All 96 patients were treated with a bolus intravenous injection of mitomycin C (MMC) plus oral administration of tegafur (FT-207, FT). The survival rate of the patients in the MMC+FT+Bestatin group was more favorable than that of the patients in the MMC+FT group, but the difference was not statistically significant. The survival rates of the MMC+FT+Bestatin group patients in the stratification of stage III+IV and positive histological serosal invasion, ps(+), were significantly superior to those of the MMC+FT group patients (Logrank test: p less than 0.05). Moreover, in patients with positive histological serosal invasion, the recurrence of peritoneal dissemination was significantly suppressed in the MMC+FT+Bestatin group.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antibiotics, Antineoplastic / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Leucine / analogs & derivatives*
  • Leucine / therapeutic use
  • Middle Aged
  • Mitomycins / therapeutic use
  • Neoplasm Staging
  • Prospective Studies
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology
  • Tegafur / therapeutic use


  • Antibiotics, Antineoplastic
  • Mitomycins
  • Tegafur
  • Leucine
  • ubenimex